Aromatase inhibitors, GnRH analogs and growth hormone for short stature with advanced bone age in adolescent boys: A Bayesian network meta-analysis
Pooled result · ΔPAHResult — go to the resultMD +3.58 cm 95% CrI 1.83–5.14Authors' conclusion
In adolescent boys with advanced bone age, AI+GH was the highest-ranked strategy for improving predicted and final adult height, ahead of GnRHa+GH and monotherapy
Study context
- Population
- Adolescent boys with short stature, reduced predicted adult height and advanced bone age (BA/CA >1)
- Participants
- 651 participants8 observational studies
- Comparison
- Aromatase inhibitors (AI)+growth hormone (GH) vs GnRH analogs (GnRHa)+GH vs AI alone vs GH alone
- Outcome
- Change in predicted adult height (ΔPAH)
Methodological detailsPROSPERO-registered, PRISMA-NMA, prespecified letrozole-versus-anastrozole sensitivity analysis, CINeMA certainty rating
- PROSPERO-registered
- PRISMA-NMA
- Prespecified letrozole-versus-anastrozole sensitivity analysis
- CINeMA certainty rating
Pooled result
ΔPAH
MD
+3.58 cm
95% CrI 1.83–5.14
As reported in the abstract
- AI+GH ranked first for ΔPAH (SUCRA)
- 0.99
Further pooled results
| Outcome | MD (cm) (95% CrI) |
|---|---|
| Final adult heightAI+GH vs GH · CrI | +2.70 (0.12–5.16) |
Height standard deviation score (SDS) for chronological age, ΔBA/ΔCA and height SDS for bone age
- AI+GH ranked highest for height SDS for chronological age and ΔBA/ΔCA
- AI+GH tied with GnRHa+GH for height SDS for bone age
Safety
| Outcome | AI+GH | GnRHa+GH | GH |
|---|---|---|---|
| Hyperuricemia | 47% | 0% | 0% |
Original publication
Aromatase inhibitors, GnRH analogs and growth hormone for short stature with advanced bone age in adolescent boys: A Bayesian network meta-analysis. Endocr Pract. Published 17 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →